CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants.

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended for patients who have not responded to two other, conventional antidepressants which can ...

though only a molecule of ketamine called esketamine that’s used in smaller doses is active in Spravato. Ketamine is also sometimes distributed illegally, mostly after being stolen from ...

6 The mechanism by which esketamine exerts its antidepressant effect is unknown. Backed by more than a decade of research and almost six years of real-world evidence, SPRAVATO ® has proven to be ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

Esketamine, which Spravato is derived from, is a molecule related to the anesthetic ketamine. According to the manufacturer, Spravato works by targeting glutamate, which is the brain's most ...